Patents by Inventor Christopher Douglas Paluch

Christopher Douglas Paluch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ENGINEERED CD200R ANTIBODIES AND USES THEREOF
    Publication number: 20230416361
    Abstract: In some aspects, provided herein are antibodies or antigen-binding fragments that bind to CD200R, a glycoprotein receptor present on cell surfaces. Antibodies or antigen-binding fragments provided herein, in some cases, agonize CD200R signaling pathway that inhibits inflammation and immune response. In other aspects, provided herein are compositions, methods of use, methods of making, polynucleotides, vectors, host cells, and kits relating to antibodies or antigen-binding fragments that bind to CD200R.
    Type: Application
    Filed: April 5, 2023
    Publication date: December 28, 2023
    Inventors: Simon John DAVIS, Richard John CORNALL, Christopher Douglas PALUCH, Lynne Anne MURRAY, Nathan Jacob ROBERTSON, Eleanor Marysia SCOTT, Daniela M. TOMAZELA
  • BTLA antibodies
    Patent number: 11421030
    Abstract: This invention relates generally to antibodies or antigen binding fragments that bind to human B and T lymphocyte attenuator (BTLA) and uses thereof. More specifically, the invention relates to agonistic antibodies that bind human BTLA and modulate its activity, and their use in treating inflammatory, autoimmune and proliferative diseases and disorders.
    Type: Grant
    Filed: May 25, 2021
    Date of Patent: August 23, 2022
    Assignees: MiroBio Limited, Oxford University Innovation Limited
    Inventors: Simon John Davis, Richard John Cornall, Christopher Douglas Paluch
  • BTLA ANTIBODIES
    Publication number: 20220177589
    Abstract: This invention relates generally to antibodies or antigen binding fragments that bind to human B and T lymphocyte attenuator (BTLA) and uses thereof. More specifically, the invention relates to agonistic antibodies that bind human BTLA and modulate its activity, and their use in treating inflammatory, autoimmune and proliferative diseases and disorders.
    Type: Application
    Filed: December 27, 2021
    Publication date: June 9, 2022
    Inventors: Simon John Davis, Richard John Cornall, Christopher Douglas Paluch
  • BTLA ANTIBODIES
    Publication number: 20210277123
    Abstract: This invention relates generally to antibodies or antigen binding fragments that bind to human B and T lymphocyte attenuator (BTLA) and uses thereof. More specifically, the invention relates to agonistic antibodies that bind human BTLA and modulate its activity, and their use in treating inflammatory, autoimmune and proliferative diseases and disorders.
    Type: Application
    Filed: May 25, 2021
    Publication date: September 9, 2021
    Inventors: Simon John Davis, Richard John Cornall, Christopher Douglas Paluch